Jeffrey M. Witkin - Publications

Affiliations: 
Eli Lilly, Indianapolis, IN, United States 

101 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Knopp KL, Simmons RMA, Guo W, Adams BL, Gardinier KM, Gernert DL, Ornstein PL, Porter W, Reel J, Ding C, Wang H, Qian Y, Burris KD, Need A, Barth V, ... ... Witkin J, et al. Modulation of TARP γ8-containing AMPA Receptors as a Novel Therapeutic Approach for Chronic Pain. The Journal of Pharmacology and Experimental Therapeutics. PMID 30910921 DOI: 10.1124/Jpet.118.250126  0.322
2018 Witkin JM, Shenvi RA, Li X, Gleason SD, Weiss J, Morrow D, Catow JT, Wakulchik M, Ohtawa M, Lu HH, Martinez MD, Schkeryantz JM, Carpenter TS, Lightstone FC, Cerne R. Pharmacological characterization of the neurotrophic sesquiterpene jiadifenolide reveals a non-convulsant signature and potential for progression in neurodegenerative disease studies. Biochemical Pharmacology. PMID 29940173 DOI: 10.1016/J.Bcp.2018.06.022  0.384
2018 Witkin JM, Smith JL, Ping X, Gleason SD, Poe MM, Li G, Jin X, Hobbs J, Schkeryantz JM, McDermott JS, Alatorre AI, Siemian JN, Cramer JW, Airey DC, Methuku KR, et al. Bioisosteres of ethyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo [1,5-a][1,4]diazepine-3-carboxylate (HZ-166) as novel alpha 2,3 selective potentiators of GABA receptors: Improved bioavailability enhances anticonvulsant efficacy. Neuropharmacology. 137: 332-343. PMID 29778948 DOI: 10.1016/J.Neuropharm.2018.05.006  0.357
2018 Methuku KR, Li X, Cerne R, Gleason SD, Schkeryantz JM, Tiruveedhula VVNPB, Golani LK, Li G, Poe MM, Rahman MT, Cook JM, Fisher JL, Witkin JM. An antidepressant-related pharmacological signature for positive allosteric modulators of α2/3-containing GABA receptors. Pharmacology, Biochemistry, and Behavior. PMID 29715490 DOI: 10.1016/J.Pbb.2018.04.009  0.308
2018 Xu NZ, Ernst M, Treven M, Cerne R, Wakulchik M, Li X, Jones TM, Gleason SD, Morrow D, Schkeryantz JM, Rahman MT, Li G, Poe MM, Cook JM, Witkin JM. Negative allosteric modulation of alpha 5-containing GABAA receptors engenders antidepressant-like effects and selectively prevents age-associated hyperactivity in tau-depositing mice. Psychopharmacology. PMID 29374303 DOI: 10.1007/S00213-018-4832-9  0.316
2017 Bruns RF, Mitchell SN, Wafford KA, Harper AJ, Shanks EA, Carter G, O'Neill MJ, Murray TK, Eastwood BJ, Schaus JM, Beck JP, Hao J, Witkin JM, Li X, Chernet E, et al. Preclinical profile of a dopamine D1 potentiator suggests therapeutic utility in neurological and psychiatric disorders. Neuropharmacology. PMID 29102759 DOI: 10.1016/J.Neuropharm.2017.10.032  0.364
2017 Witkin JM, Schober DA, Gleason SD, Catlow JT, Porter WJ, Reel J, Jin X, Hobbs J, Gehlert D, Gernert DL, Gardinier KM, Kato AS, Ping X, Smith JL. Targeted Blockade of TARP-g8-Associated AMPA Receptors: Anticonvulsant Activity with the Selective Antagonist LY3130481 (CERC-611). Cns & Neurological Disorders Drug Targets. PMID 29090671 DOI: 10.2174/1871527316666171101132047  0.355
2017 Kato AS, Witkin JM. Auxiliary subunits of AMPA receptors: the discovery of a forebrain-selective antagonist, LY3130481/CERC-611. Biochemical Pharmacology. PMID 28987594 DOI: 10.1016/J.Bcp.2017.09.015  0.331
2017 Yuen E, Swanson S, Witkin JM. Prediction of human efficacious antidepressant doses using the mouse forced swim test. Pharmacology, Biochemistry, and Behavior. PMID 28888484 DOI: 10.1016/J.Pbb.2017.09.002  0.332
2017 Lee MR, Gardinier KM, Gernert DL, Schober DA, Wright RA, Wang H, Qian Y, Witkin JM, Nisenbaum ES, Kato AS. Structural Determinants of the γ-8 TARP Dependent AMPA Receptor Antagonist. Acs Chemical Neuroscience. PMID 28825787 DOI: 10.1021/Acschemneuro.7B00186  0.308
2017 Witkin JM, Li J, Gilmour G, Mitchell SN, Carter G, Gleason SD, Seidel WF, Eastwood BJ, McCarthy A, Porter WJ, Reel J, Gardinier KM, Kato AS, Wafford KA. Electroencephalographic, cognitive, and neurochemical effects of LY3130481 (CERC-611), a selective antagonist of TARP-γ8-associated AMPA receptors. Neuropharmacology. PMID 28757050 DOI: 10.1016/J.Neuropharm.2017.07.028  0.346
2017 Rodriguez MM, Overshiner C, Leander JD, Li X, Morrow D, Conway RG, Nelson DL, Briner K, Witkin JM. Behavioral Effects of a Novel Benzofuranyl-Piperazine Serotonin-2C Receptor Agonist Suggest a Potential Therapeutic Application in the Treatment of Obsessive-Compulsive Disorder. Frontiers in Psychiatry. 8: 89. PMID 28588509 DOI: 10.3389/Fpsyt.2017.00089  0.616
2017 Witkin JM, Cerne R, Wakulchik M, S J, Gleason SD, Jones TM, Li G, Arnold LA, Li JX, Schkeryantz JM, Methuku KR, Cook JM, Poe MM. Further evaluation of the potential anxiolytic activity of imidazo[1,5-a][1,4]diazepin agents selective for α2/3-containing GABAA receptors. Pharmacology, Biochemistry, and Behavior. PMID 28442369 DOI: 10.1016/J.Pbb.2017.04.009  0.354
2016 Witkin JM, Rorick-Kehn LM, Benvenga MJ, Adams BL, Gleason SD, Knitowski KM, Li X, Chaney S, Falcone JF, Smith JW, Foss J, Lloyd K, Catlow JT, McKinzie DL, Svensson KA, et al. Preclinical findings predicting efficacy and side-effect profile of LY2940094, an antagonist of nociceptin receptors. Pharmacology Research & Perspectives. 4: e00275. PMID 28097008 DOI: 10.1002/Prp2.275  0.395
2016 Poe MM, Methuku KR, Li G, Verma AR, Teske KA, Stafford DC, Arnold LA, Cramer JW, Jones TM, Cerne R, Krambis MJ, Witkin JM, Jambrina E, Rehman S, Ernst M, et al. Synthesis and Characterization of a Novel γ-Aminobutyric Acid Type A (GABAA) Receptor Ligand That Combines Outstanding Metabolic Stability, Pharmacokinetics, and Anxiolytic Efficacy. Journal of Medicinal Chemistry. 59: 10800-10806. PMID 27933953 DOI: 10.1021/Acs.Jmedchem.6B01332  0.32
2016 Dressman BA, Tromiczak EG, Chappell MD, Tripp AE, Quimby SJ, Vetman T, Fivush AM, Matt J, Jaramillo C, Li R, Khilevich A, Blanco MJ, Smith SC, Carpintero M, de Diego JE, ... ... Witkin JM, et al. Novel bicyclo[3.1.0]hexane analogs as antagonists of metabotropic glutamate 2/3 receptors for the treatment of depression. Bioorganic & Medicinal Chemistry Letters. PMID 27836401 DOI: 10.1016/J.Bmcl.2016.10.067  0.36
2016 Kato AS, Burris KD, Gardinier KM, Gernert DL, Porter WJ, Reel J, Ding C, Tu Y, Schober DA, Lee MR, Heinz BA, Fitch TE, Gleason SD, Catlow JT, Yu H, ... ... Witkin JM, et al. Forebrain-selective AMPA-receptor antagonism guided by TARP γ-8 as an antiepileptic mechanism. Nature Medicine. PMID 27820603 DOI: 10.1038/Nm.4221  0.348
2016 Eiler WJ, Chen Y, Slieker LJ, Ardayfio PA, Statnick MA, Witkin JM. Consequences of constitutive deletion of melanin-concentrating hormone-1 receptors for feeding and foraging behaviors of mice. Behavioural Brain Research. 316: 271-278. PMID 27633558 DOI: 10.1016/J.Bbr.2016.09.028  0.32
2016 Witkin JM, Monn JA, Schoepp DD, Li X, Overshiner CD, Mitchell SN, Carter G, Johnson B, Rasmussen K, Rorick-Kehn LM. The Rapidly-Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits. The Journal of Pharmacology and Experimental Therapeutics. PMID 27189960 DOI: 10.1124/Jpet.116.233627  0.37
2016 Rorick-Kehn LM, Ciccocioppo R, Wong CJ, Witkin JM, Martinez-Grau MA, Stopponi S, Adams BL, Katner JS, Perry KW, Toledo MA, Diaz N, Lafuente C, Jiménez A, Benito A, Pedregal C, et al. A Novel, Orally Bioavailable Nociceptin Receptor Antagonist, LY2940094, Reduces Ethanol Self-Administration and Ethanol Seeking in Animal Models. Alcoholism, Clinical and Experimental Research. PMID 27084498 DOI: 10.1111/Acer.13052  0.36
2016 Gardinier KM, Gernert DL, Porter WJ, Reel JK, Ornstein PL, Spinazze P, Stevens FC, Hahn P, Hollinshead SP, Mayhugh D, Schkeryantz J, Khilevich A, De Frutos O, Gleason SD, Kato AS, ... ... Witkin JM, et al. The Discovery of The First α-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid (AMPA) Receptor Antagonist Dependent Upon Transmembrane AMPA Receptor Regulatory Protein (TARP) Gamma-8. Journal of Medicinal Chemistry. PMID 27067148 DOI: 10.1021/Acs.Jmedchem.6B00125  0.342
2015 Witkin JM, Ornstein PL, Mitch CH, Li R, Smith SC, Heinz BA, Wang XS, Xiang C, Carter JH, Anderson WH, Li X, Broad LM, Pasqui F, Fitzjohn SM, Sanger HE, et al. In Vitro Pharmacological and Rat Pharmacokinetic Characterization of LY3020371, a Potent and Selective mGlu2/3 Receptor Antagonist. Neuropharmacology. PMID 26748052 DOI: 10.1016/J.Neuropharm.2015.12.021  0.333
2015 Post A, Smart TS, Krikke-Workel J, Dawson GR, Harmer CJ, Browning M, Jackson K, Kakar R, Mohs R, Statnick M, Wafford K, McCarthy A, Barth V, Witkin JM. A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical Studies. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 26585287 DOI: 10.1038/Npp.2015.348  0.354
2015 Witkin JM, Gleason SD, Carter RB, Dykstra LA. Obituary: J. David LEander, Ph.D. : (April 8, 1944-November 14, 2014). Psychopharmacology. 232: 1175-6. PMID 25697862 DOI: 10.1007/S00213-015-3885-2  0.692
2014 Witkin JM, Overshiner C, Li X, Catlow JT, Wishart GN, Schober DA, Heinz BA, Nikolayev A, Tolstikov VV, Anderson WH, Higgs RE, Kuo MS, Felder CC. M1 and m2 muscarinic receptor subtypes regulate antidepressant-like effects of the rapidly acting antidepressant scopolamine. The Journal of Pharmacology and Experimental Therapeutics. 351: 448-56. PMID 25187432 DOI: 10.1124/Jpet.114.216804  0.326
2014 Toledo MA, Pedregal C, Lafuente C, Diaz N, Martinez-Grau MA, Jiménez A, Benito A, Torrado A, Mateos C, Joshi EM, Kahl SD, Rash KS, Mudra DR, Barth VN, Shaw DB, ... ... Witkin JM, et al. Discovery of a novel series of orally active nociceptin/orphanin FQ (NOP) receptor antagonists based on a dihydrospiro(piperidine-4,7'-thieno[2,3-c]pyran) scaffold. Journal of Medicinal Chemistry. 57: 3418-29. PMID 24678969 DOI: 10.1021/Jm500117R  0.35
2014 Witkin JM, Statnick MA, Rorick-Kehn LM, Pintar JE, Ansonoff M, Chen Y, Tucker RC, Ciccocioppo R. The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence. Pharmacology & Therapeutics. 141: 283-99. PMID 24189487 DOI: 10.1016/J.Pharmthera.2013.10.011  0.334
2014 Rorick-Kehn LM, Witkin JM, Statnick MA, Eberle EL, McKinzie JH, Kahl SD, Forster BM, Wong CJ, Li X, Crile RS, Shaw DB, Sahr AE, Adams BL, Quimby SJ, Diaz N, et al. LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. Neuropharmacology. 77: 131-44. PMID 24071566 DOI: 10.1016/J.Neuropharm.2013.09.021  0.402
2013 Barth V, Need AB, Tzavara ET, Giros B, Overshiner C, Gleason SD, Wade M, Johansson AM, Perry K, Nomikos GG, Witkin JM. In vivo occupancy of dopamine D3 receptors by antagonists produces neurochemical and behavioral effects of potential relevance to attention-deficit-hyperactivity disorder. The Journal of Pharmacology and Experimental Therapeutics. 344: 501-10. PMID 23197772 DOI: 10.1124/Jpet.112.198895  0.357
2011 Eiler WJ, Baez M, Yu J, Witkin JM. mGlu5 receptor deletion reduces relapse to food-seeking and prevents the anti-relapse effects of mGlu5 receptor blockade in mice. Life Sciences. 89: 862-7. PMID 21983299 DOI: 10.1016/J.Lfs.2011.09.014  0.358
2011 Kaminski RM, Núñez-Taltavull JF, Budziszewska B, LasoÅ„ W, Gasior M, Zapata A, Shippenberg TS, Witkin JM. Effects of cocaine-kindling on the expression of NMDA receptors and glutamate levels in mouse brain. Neurochemical Research. 36: 146-52. PMID 20927585 DOI: 10.1007/S11064-010-0284-2  0.329
2010 Farley S, Apazoglou K, Witkin JM, Giros B, Tzavara ET. Antidepressant-like effects of an AMPA receptor potentiator under a chronic mild stress paradigm. The International Journal of Neuropsychopharmacology / Official Scientific Journal of the Collegium Internationale Neuropsychopharmacologicum (Cinp). 13: 1207-18. PMID 20059803 DOI: 10.1017/S1461145709991076  0.353
2008 Chan WY, McKinzie DL, Bose S, Mitchell SN, Witkin JM, Thompson RC, Christopoulos A, Lazareno S, Birdsall NJ, Bymaster FP, Felder CC. Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia. Proceedings of the National Academy of Sciences of the United States of America. 105: 10978-83. PMID 18678919 DOI: 10.1073/Pnas.0800567105  0.33
2008 Pilc A, Chaki S, Nowak G, Witkin JM. Mood disorders: regulation by metabotropic glutamate receptors. Biochemical Pharmacology. 75: 997-1006. PMID 18164691 DOI: 10.1016/J.Bcp.2007.09.021  0.335
2007 O'Neill MJ, Witkin JM. AMPA receptor potentiators: application for depression and Parkinson's disease. Current Drug Targets. 8: 603-20. PMID 17504104 DOI: 10.2174/138945007780618517  0.322
2007 Witkin JM, Baez M, Yu J, Barton ME, Shannon HE. Constitutive deletion of the serotonin-7 (5-HT(7)) receptor decreases electrical and chemical seizure thresholds. Epilepsy Research. 75: 39-45. PMID 17485199 DOI: 10.1016/J.Eplepsyres.2007.03.017  0.355
2007 Witkin JM, Marek GJ, Johnson BG, Schoepp DD. Metabotropic glutamate receptors in the control of mood disorders. Cns & Neurological Disorders Drug Targets. 6: 87-100. PMID 17430147 DOI: 10.2174/187152707780363302  0.334
2007 Svenningsson P, Tzavara ET, Qi H, Carruthers R, Witkin JM, Nomikos GG, Greengard P. Biochemical and behavioral evidence for antidepressant-like effects of 5-HT6 receptor stimulation. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 27: 4201-9. PMID 17428998 DOI: 10.1523/Jneurosci.3110-06.2007  0.322
2007 Alt A, Weiss B, Ornstein PL, Gleason SD, Bleakman D, Stratford RE, Witkin JM. Anxiolytic-like effects through a GLUK5 kainate receptor mechanism. Neuropharmacology. 52: 1482-7. PMID 17418283 DOI: 10.1016/J.Neuropharm.2007.02.005  0.346
2007 Rorick-Kehn LM, Johnson BG, Knitowski KM, Salhoff CR, Witkin JM, Perry KW, Griffey KI, Tizzano JP, Monn JA, McKinzie DL, Schoepp DD. In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders. Psychopharmacology. 193: 121-36. PMID 17384937 DOI: 10.1007/S00213-007-0758-3  0.395
2007 Kaminski RM, Witkin JM, Shippenberg TS. Pharmacological and genetic manipulation of kappa opioid receptors: effects on cocaine- and pentylenetetrazol-induced convulsions and seizure kindling. Neuropharmacology. 52: 895-903. PMID 17126860 DOI: 10.1016/J.Neuropharm.2006.10.007  0.375
2006 Alt A, Weiss B, Ogden AM, Li X, Gleason SD, Calligaro DO, Bleakman D, Witkin JM. In vitro and in vivo studies in rats with LY293558 suggest AMPA/kainate receptor blockade as a novel potential mechanism for the therapeutic treatment of anxiety disorders. Psychopharmacology. 185: 240-7. PMID 16470401 DOI: 10.1007/S00213-005-0292-0  0.368
2006 Alt A, Nisenbaum ES, Bleakman D, Witkin JM. A role for AMPA receptors in mood disorders. Biochemical Pharmacology. 71: 1273-88. PMID 16442080 DOI: 10.1016/J.Bcp.2005.12.022  0.344
2006 Smith DG, Davis RJ, Rorick-Kehn L, Morin M, Witkin JM, McKinzie DL, Nomikos GG, Gehlert DR. Melanin-concentrating hormone-1 receptor modulates neuroendocrine, behavioral, and corticolimbic neurochemical stress responses in mice. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 31: 1135-45. PMID 16205780 DOI: 10.1038/Sj.Npp.1300913  0.326
2006 Li X, Morrow D, Witkin JM. Decreases in nestlet shredding of mice by serotonin uptake inhibitors: comparison with marble burying. Life Sciences. 78: 1933-9. PMID 16182315 DOI: 10.1016/J.Lfs.2005.08.002  0.385
2005 Witkin JM, Tzavara ET, Davis RJ, Li X, Nomikos GG. A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders. Trends in Pharmacological Sciences. 26: 609-17. PMID 16260047 DOI: 10.1016/J.Tips.2005.10.006  0.347
2005 Kaminski RM, Shippenberg TS, Witkin JM, Rocha BA. Genetic deletion of the norepinephrine transporter decreases vulnerability to seizures. Neuroscience Letters. 382: 51-5. PMID 15911120 DOI: 10.1016/J.Neulet.2005.02.056  0.344
2004 Gasior M, Witkin JM, Goldberg SR, Munzar P. Chlormethiazole potentiates the discriminative stimulus effects of methamphetamine in rats. European Journal of Pharmacology. 494: 183-9. PMID 15212973 DOI: 10.1016/J.Ejphar.2004.05.011  0.43
2004 Witkin JM, Morrow D, Li X. A rapid punishment procedure for detection of anxiolytic compounds in mice. Psychopharmacology. 172: 52-7. PMID 14504684 DOI: 10.1007/S00213-003-1618-4  0.345
2003 Kaminski RM, Gasior M, Carter RB, Witkin JM. Protective efficacy of neuroactive steroids against cocaine kindled-seizures in mice. European Journal of Pharmacology. 474: 217-22. PMID 12921865 DOI: 10.1016/S0014-2999(03)02086-7  0.666
2003 Tzavara ET, Davis RJ, Perry KW, Li X, Salhoff C, Bymaster FP, Witkin JM, Nomikos GG. The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. British Journal of Pharmacology. 138: 544-53. PMID 12598408 DOI: 10.1038/Sj.Bjp.0705100  0.317
2003 Zapata A, Gasior M, Geter-Douglass B, Tortella FC, Newman AH, Witkin JM. Attenuation of the stimulant and convulsant effects of cocaine by 17-substituted-3-hydroxy and 3-alkoxy derivatives of dextromethorphan. Pharmacology, Biochemistry, and Behavior. 74: 313-23. PMID 12479950 DOI: 10.1016/S0091-3057(02)01000-6  0.365
2002 Witkin JM, Gasior M, Schad C, Zapata A, Shippenberg T, Hartman T, Slusher BS. NAALADase (GCP II) inhibition prevents cocaine-kindled seizures. Neuropharmacology. 43: 348-56. PMID 12243764 DOI: 10.1016/S0028-3908(02)00124-7  0.353
2002 Gasior M, Jaszyna M, Munzar P, Witkin JM, Goldberg SR. Caffeine potentiates the discriminative-stimulus effects of nicotine in rats. Psychopharmacology. 162: 385-95. PMID 12172692 DOI: 10.1007/S00213-002-1113-3  0.31
2002 Svenningsson P, Tzavara ET, Witkin JM, Fienberg AA, Nomikos GG, Greengard P. Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). Proceedings of the National Academy of Sciences of the United States of America. 99: 3182-7. PMID 11880651 DOI: 10.1073/Pnas.052712799  0.308
2001 Zapata A, Witkin JM, Shippenberg TS. Selective D3 receptor agonist effects of (+)-PD 128907 on dialysate dopamine at low doses. Neuropharmacology. 41: 351-9. PMID 11522326 DOI: 10.1016/S0028-3908(01)00069-7  0.341
2001 Lindén A, Storvik M, Lakso M, Haapasalo A, Lee D, Witkin JM, Sei Y, Castrén E, Wong G. Increased expression of neuronal Src and tyrosine phosphorylation of NMDA receptors in rat brain after systemic treatment with MK-801. Neuropharmacology. 40: 469-81. PMID 11249956 DOI: 10.1016/S0028-3908(00)00185-4  0.344
2000 Ungard JT, Beekman M, Gasior M, Carter RB, Dijkstra D, Witkin JM. Modification of behavioral effects of drugs in mice by neuroactive steroids. Psychopharmacology. 148: 336-43. PMID 10928304 DOI: 10.1007/S002130050060  0.702
2000 Gasior M, Ungard JT, Beekman M, Carter RB, Witkin JM. Acute and chronic effects of the synthetic neuroactive steroid, ganaxolone, against the convulsive and lethal effects of pentylenetetrazol in seizure-kindled mice: comparison with diazepam and valproate. Neuropharmacology. 39: 1184-96. PMID 10760361 DOI: 10.1016/S0028-3908(99)00190-2  0.687
2000 Gasior M, Ungard JT, Witkin JM. Lethal seizures predicted after aminophylline therapy in cocaine abusers. European Journal of Pharmacology. 387: R15-6. PMID 10650168 DOI: 10.1016/S0014-2999(99)00801-8  0.319
1999 Gasior M, Carter RB, Witkin JM. Neuroactive steroids: potential therapeutic use in neurological and psychiatric disorders. Trends in Pharmacological Sciences. 20: 107-12. PMID 10203866 DOI: 10.1016/S0165-6147(99)01318-8  0.671
1998 Beekman M, Ungard JT, Gasior M, Carter RB, Dijkstra D, Goldberg SR, Witkin JM. Reversal of behavioral effects of pentylenetetrazol by the neuroactive steroid ganaxolone. The Journal of Pharmacology and Experimental Therapeutics. 284: 868-77. PMID 9495844  0.686
1998 Gasior M, Beekman M, Carter RB, Goldberg SR, Witkin JM. Antiepileptogenic effects of the novel synthetic neuroactive steroid, ganaxolone, against pentylenetetrazol-induced kindled seizures: Comparison with diazepam and valproate Drug Development Research. 44: 21-33. DOI: 10.1002/(Sici)1098-2299(199805)44:1<21::Aid-Ddr4>3.0.Co;2-R  0.689
1997 Gasior M, Carter RB, Goldberg SR, Witkin JM. Anticonvulsant and behavioral effects of neuroactive steroids alone and in conjunction with diazepam. The Journal of Pharmacology and Experimental Therapeutics. 282: 543-53. PMID 9262314  0.671
1997 Witkin JM, Acri JB, Gleeson S, Barrett JE. Blockade of behavioral effects of bretazenil by flumazenil and ZK 93,426 in pigeons. Pharmacology, Biochemistry, and Behavior. 56: 1-7. PMID 8981602 DOI: 10.1016/S0091-3057(96)00120-7  0.566
1996 Witkin JM, Acri JB, Wong G, Gleeson S, Barrett JE. Behavioral and biochemical characterization of benzodiazepine receptor partial agonists in pigeons. The Journal of Pharmacology and Experimental Therapeutics. 277: 87-96. PMID 8613971  0.508
1995 Katz JL, Alling K, Shores E, Witkin JM. Effects of D1 dopamine agonists on schedule-controlled behavior in the squirrel monkey. Behavioural Pharmacology. 6: 143-148. PMID 11224321  0.305
1995 Acri JB, Carter SR, Alling K, Geter-Douglass B, Dijkstra D, Wikström H, Katz JL, Witkin JM. Assessment of cocaine-like discriminative stimulus effects of dopamine D3 receptor ligands. European Journal of Pharmacology. 281: R7-9. PMID 7589197 DOI: 10.1016/0014-2999(95)00411-D  0.332
1993 Katz JL, Witkin JM. Behavioral effects of dopaminergic agonists and antagonists alone and in combination in the squirrel monkey. Psychopharmacology. 113: 19-25. PMID 7862823 DOI: 10.1007/Bf02244328  0.31
1992 Witkin JM, Genovese RF, Witkin KM, Chiang PK. Behavioral effects of some diphenyl-substituted antimuscarinics: comparison with cocaine and atropine. Pharmacology, Biochemistry, and Behavior. 41: 377-84. PMID 1574528 DOI: 10.1016/0091-3057(92)90114-U  0.623
1991 Witkin JM, Johnson RE, Jaffe JH, Goldberg SR, Grayson NA, Rice KC, Katz JL. The partial opioid agonist, buprenorphine, protects against lethal effects of cocaine. Drug and Alcohol Dependence. 27: 177-84. PMID 1647294 DOI: 10.1016/0376-8716(91)90037-Y  0.368
1991 Terry P, Witkin J, Katz J. Changes in the stimulus effects of cocaine with training dose Pharmacology Biochemistry and Behavior. 39: 246. DOI: 10.1016/0091-3057(91)90534-9  0.315
1990 Katz JL, Tirelli E, Witkin JM. Stereoselective effects of cocaine. Behavioural Pharmacology. 1: 347-353. PMID 11175419 DOI: 10.1097/00008877-199000140-00008  0.348
1990 Genovese RF, Elsmore TF, Witkin JM. Relationship of the behavioral effects of aprophen, atropine and scopolamine to antagonism of the behavioral effects of physostigmine. Pharmacology, Biochemistry, and Behavior. 37: 117-22. PMID 2263653 DOI: 10.1016/0091-3057(90)90051-I  0.623
1990 Katz JL, Dworkin SI, Dykstra LA, Carter RB, Witkin JM. Some behavioral effects of repeated d-amphetamine administrations Drug Development Research. 20: 31-41. DOI: 10.1002/Ddr.430200105  0.735
1989 Witkin JM, Markowitz RA, Barrett JE. Physostigmine-insensitive behavioral excitatory effects of atropine in squirrel monkeys. Pharmacology, Biochemistry, and Behavior. 32: 309-15. PMID 2734342 DOI: 10.1016/0091-3057(89)90248-7  0.401
1989 Witkin JM, Goldberg SR, Katz JL, Kuhar MJ. Modulation of the lethal effects of cocaine by cholinomimetics. Life Sciences. 45: 2295-301. PMID 2601580 DOI: 10.1016/0024-3205(89)90111-2  0.333
1989 Witkin JM, Goldberg SR, Katz JL. Lethal effects of cocaine are reduced by the dopamine-1 receptor antagonist SCH 23390 but not by haloperidol. Life Sciences. 44: 1285-91. PMID 2523996 DOI: 10.1016/0024-3205(89)90366-4  0.356
1988 Genovese RF, Elsmore TF, Witkin JM. Environmental influences on the development of tolerance to the effects of physostigmine on schedule-controlled behavior. Psychopharmacology. 96: 462-7. PMID 3149767 DOI: 10.1007/Bf02180025  0.623
1988 Witkin JM, Brady LS, Barrett JE. Antagonism by ketanserin of the behavioral effects of quipazine but not l-5-hydroxytryptophan in squirrel monkeys. Psychopharmacology. 94: 302-5. PMID 3128804 DOI: 10.1007/Bf00174679  0.505
1988 Mansbach RS, Harrod C, Hoffmann SM, Nader MA, Lei Z, Witkin JM, Barrett JE. Behavioral studies with anxiolytic drugs. V. Behavioral and in vivo neurochemical analyses in pigeons of drugs that increase punished responding. The Journal of Pharmacology and Experimental Therapeutics. 246: 114-20. PMID 2455786  0.401
1987 Witkin JM, Mansbach RS, Barrett JE, Bolger GT, Skolnick P, Weissman B. Behavioral studies with anxiolytic drugs. IV. Serotonergic involvement in the effects of buspirone on punished behavior of pigeons. The Journal of Pharmacology and Experimental Therapeutics. 243: 970-7. PMID 2891840  0.401
1986 Witkin JM, Barrett JE, Cook JM, Larscheid P. Differential antagonism of diazepam-induced loss of the righting response. Pharmacology, Biochemistry, and Behavior. 24: 963-5. PMID 3012601 DOI: 10.1016/0091-3057(86)90443-0  0.401
1986 Witkin JM, Barrett JE. Benzodiazepine-like effects of inosine on punished behavior of pigeons. Pharmacology, Biochemistry, and Behavior. 24: 121-5. PMID 3003762 DOI: 10.1016/0091-3057(86)90054-7  0.521
1986 Barrett JE, Witkin JM, Mansbach RS, Skolnick P, Weissman BA. Behavioral studies with anxiolytic drugs. III. Antipunishment actions of buspirone in the pigeon do not involve benzodiazepine receptor mechanisms. The Journal of Pharmacology and Experimental Therapeutics. 238: 1009-13. PMID 2875168  0.528
1986 Witkin JM, Barrett JE. Interaction of buspirone and dopaminergic agents on punished behavior of pigeons. Pharmacology, Biochemistry, and Behavior. 24: 751-6. PMID 2871566 DOI: 10.1016/0091-3057(86)90585-X  0.512
1986 Barrett JE, Brady LS, Stanley JA, Mansbach RS, Witkin JM. Behavioral studies with anxiolytic drugs. II. Interactions of zopiclone with ethyl-beta-carboline-3-carboxylate and Ro 15-1788 in squirrel monkeys. The Journal of Pharmacology and Experimental Therapeutics. 236: 313-9. PMID 2868115  0.494
1985 Barrett JE, Brady LS, Witkin JM, Cook JM, Larscheid P. Interactions between the benzodiazepine receptor antagonist Ro 15-1788 (flumazepil) and the inverse agonist beta-CCE: behavioral studies with squirrel monkeys. Life Sciences. 36: 1407-14. PMID 3920465 DOI: 10.1016/0024-3205(85)90047-5  0.467
1985 Bolger GT, Weissman BA, Lueddens H, Basile AS, Mantione CR, Barrett JE, Witkin JM, Paul SM, Skolnick P. Late evolutionary appearance of 'peripheral-type' binding sites for benzodiazepines. Brain Research. 338: 366-70. PMID 2992689 DOI: 10.1016/0006-8993(85)90170-2  0.372
1985 Barrett JE, Brady LS, Witkin JM. Behavioral studies with anxiolytic drugs. I. Interactions of the benzodiazepine antagonist Ro 15-1788 with chlordiazepoxide, pentobarbital and ethanol. The Journal of Pharmacology and Experimental Therapeutics. 233: 554-9. PMID 2989486  0.507
1985 Witkin JM, Barrett JE. Behavioral effects and benzodiazepine antagonist activity of Ro 15-1788 (flumazepil) in pigeons. Life Sciences. 37: 1587-95. PMID 2932617 DOI: 10.1016/0024-3205(85)90477-1  0.519
1984 Witkin JM, Sickle J, Barrett JE. Potentiation of the behavioral effects of pentobarbital, chlordiazepoxide and ethanol by thyrotropin-releasing hormone. Peptides. 5: 809-13. PMID 6436800 DOI: 10.1016/0196-9781(84)90026-3  0.5
1983 Witkin JM, Leander JD, Dykstra LA. Modification of behavioral effects of morphine, meperidine and normeperidine by naloxone and by morphine tolerance. The Journal of Pharmacology and Experimental Therapeutics. 225: 275-83. PMID 6842391  0.665
1982 Witkin JM, Leander JD. Effects of orally-administered ethanol and tertiary-butanol on fixed-ratio responding of rats. Substance and Alcohol Actions/Misuse. 3: 275-9. PMID 7167864  0.506
1982 Witkin JM, Dykstra LA, Carter RB. Acute tolerance to the discriminative stimulus properties of morphine. Pharmacology, Biochemistry, and Behavior. 17: 223-8. PMID 7134234 DOI: 10.1016/0091-3057(82)90073-9  0.721
1982 Witkin JM, Leander JD. Effects of the appetite stimulant chlordimeform on food and water consumption of rats: comparison with chlordiazepoxide. The Journal of Pharmacology and Experimental Therapeutics. 223: 130-4. PMID 7120114  0.461
1981 Witkin JM, Katz JL, Barrett JE. Effects of methaqualone on punished and nonpunished behavior. The Journal of Pharmacology and Experimental Therapeutics. 218: 1-6. PMID 7241372  0.401
1981 Witkin JM, Barrett JE. Effects of pentobarbital on punished behavior: persistent increases with chronic administration. Psychopharmacology. 75: 324-5. PMID 6798626 DOI: 10.1007/BF00432448  0.437
1980 Witkin JM, Carter RB, Dykstra LA. Discriminative stimulus properties of d-amphetamine-pentobarbital combinations. Psychopharmacology. 68: 269-76. PMID 6771810 DOI: 10.1007/BF00428114  0.726
1976 Witkin JM, Barrett JE. Effects of pentobarbital on punished behavior at different shock intensities. Pharmacology, Biochemistry, and Behavior. 5: 535-8. PMID 1019183 DOI: 10.1016/0091-3057(76)90265-3  0.444
1976 Barrett JE, Witkin JM. Interaction of d-amphetamine with pentobarbital and chlordiazepoxide: effects on punished and unpunished behavior of pigeons. Pharmacology, Biochemistry, and Behavior. 5: 285-92. PMID 996061 DOI: 10.1016/0091-3057(76)90080-0  0.505
Show low-probability matches.